Chiang C-E Ferrieres J, Gotcheva NN, Raal F, Shehab A, Sung J, Henriksson KM, Hermans MP (2016). Suboptimal control of lipid levels: Results from 29 countries participating in the centralized pan-regional surveys on the undertreatment of hypercholesterolaemia (CEPHEUS) JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2016, 23 (5) pp. 567 - 587.
Daya R, Bayat Z, Raal F (2016). Effects of diabetes mellitus on health-related quality of life at a tertiary hospital in South Africa: A cross-sectional study. SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2016, 106 (9) pp. 918 - 928.
Ginsberg HN, Rader DJ, Raal F, Guyton John R, Baccara-Dinet MT, Lorenzato C, Pordy R, Stroes E (2016). Efficacy and safety of alirocumab in patients with Heterozygous familial hypercholesterolemia and LDL-C of 160mg/dl or higher. CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 pp. 473 - 483.
Merwitz B, Zamparini J, Raal F (2016). Pituitary apoplexy masquerading as meningitis JOURNAL OF ENDOCRINOLOGY, METABOLISM AND DIABETES OF SOUTH AFRICA (JEMDSA), 2016, 21 (1) pp. 38 - 39.
Pinchevsky Y, Shukla V, Butkow N, Chirwa T, Raal F (2016). Multi-ethnic differences in BhA1c, blood pressure, and low-density-lipid cholesterol control among South Africans living with type 2 diabetes, after a 4-year follow-up. INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2016, 9 pp. 1 - 8.
Raal F, Giugliano RP, Sabatine MS, Koren MJ , Blom D, Seidah NG, Honarpour N, Lira A, Xue A, et al. E (2016). PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role, JOURNAL OF LIPID RESEARCH, 2016, 57 pp. 1086 - 1096.
Raal F, Stein A (2016). The effects of Mipomersen on Inhibiting Hepatic VLDL Apolipoprotein B100 Synthesis and Propensity for Hepatic Steatosis. CLINICAL CHEMISTRY, 2016, 62 (8) pp. 1052 - 1053.
Raal F, Sjouke B, Hovingh G, Isaac BF (2016). Retrospective analysis of cohort database: pheunotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia. DATA IN BRIEF, 2016, 7 pp. 1458 - 1462.
Raal F, Sjouke B, Hovingh G, Isaac B (2016). Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. ATHEROSCLEROSIS, 2016, 248 pp. 238 - 244.
Raal F, Braamskamp MJ, Selvey SL, Sensinger CH, Kastelein J (2016). Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 pp. 860 - 869.
Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ , Watts GF, Baum SJ, Catapano AL, Chapman MJ, et al E, Raal F (2016). Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 pp. 850 - 861.
Sattar N, Preiss D , Robinson JG, Djedjos CS , Elliott M, Somaratne R, Wasserman SM, Raal F (2016). Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG145) in patients with type 2 diabetes: a meta-analysis of individual patient data. LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 pp. 403 - 410.
Stein A, Raal F (2016). Update on PCSK9 inhibitors and new therapies. US ENDOCRINOLOGY, 2016, 12 (1) pp. 18 - 21.
Stein A, Raal F (2016). Future directions to establish lipoprotein(a) as a treatment for atherosclerotic cardiovascular disease. CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (1) pp. 101 - 108.
Thedrez A, Sjouke B, Passard M, Prampart-Fauvet S, Guedon A, Croyal M, Dallinga-Thie G, Peter J, Blom D, Raal F, et al. E. (2016). Proprotein convertase subtilisin Kexin type 9 inhibition for autosomal recessive hypercholesterolemia - brief report. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 pp. 1647 - 1650.
Vallejo-vaz AJ, Akram A, Seshasai S, Cole D, Watts G, Hovingh G, Kastelein J, Mata P, Raal F, Santos-Júnior J, et al. E (2016). Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS familial hypercholesterolaemia studies collaboration. ATHEROSCLEROSIS SUPPLEMENTS, 2016, 22 pp. 1 - 32.
